WAS/WASL interacting protein family member 2Genealiases: WICH · WIRE
Q-omics provides the consensus-scored WIPF2 profile across patient tissues and cancer cell-line models. WIPF2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, WIPF2 is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, WIPF2 RNA expression shows 20,352 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, LIHC, and ACC as cancer lineages where WIPF2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for WIPF2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes WIPF2 survival associations across molecular data types. WIPF2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible WIPF2 RNA expression–survival associations across cancer types. High WIPF2 expression shows unfavorable associations in UVM, LIHC, ACC and MESO, but favorable associations in KIRC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for WIPF2 RNA expression.
This table summarizes WIPF2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for WIPF2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. WIPF2 shows lower tumor expression in KICH, COAD and THCA and higher tumor expression in LIHC, STAD and KIRP. The LIHC box plot shows higher WIPF2 RNA expression in tumor versus normal tissue (log2 FC = +1.161, t-test p < 0.001).
This table shows molecular features associated with WIPF2 in patient tissues and cancer cell lines. In patient samples, WIPF2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, WIPF2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
